Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis

Shigeaki Suzuki, Tetsuya Nishimoto, Mitsutomo Kohno, Kimiaki Utsugisawa, Yuriko Nagane, Masataka Kuwana, Norihiro Suzuki

研究成果: Article査読

11 被引用数 (Scopus)

抄録

There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.

本文言語English
ページ(範囲)61-66
ページ数6
ジャーナルJournal of Neuroimmunology
258
1-2
DOI
出版ステータスPublished - 2013

ASJC Scopus subject areas

  • 免疫アレルギー学
  • 免疫学
  • 神経学
  • 臨床神経学

フィンガープリント

「Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル